Noteworthy

Mar 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Pharm Exec's annual feature applauding the people behind the best of pharma advertising over the past year
Mar 01, 2011
Pharmaceutical Executive
Pharma can be an insular industry, with limited capacity to gaze beyond its own narrow frame of vision
Mar 01, 2011
Pharmaceutical Executive
When dealing with the pharmaceutical marketplace, why is keeping things simple so complex?
Mar 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
A highlight of the Hay Group's annual study of Sales Force Effectiveness, focusing on managed care markets
Mar 01, 2011
Pharmaceutical Executive
With an emphasis on short-term objectives rather than long-term goals, pharma is missing a huge opportunity in applying market science to drive adherence
Feb 04, 2011
Pharmaceutical Executive
"Tops in Fraud" is a ruinous moniker for pharma—a business so dependent on basic issues of trust, integrity, quality and safety
Feb 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
All this uncertainty at the back end of drug development is a drain on future therapeutic progress against disease. It's a job killer, too.
Feb 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
What are some of the essential characteristics of the US market? Statistics drawn from the 2011 Statistical Abstract of the US shed some light
Feb 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
To manage through a resource-constrained environment, it is essential to get the most out of procurement planning
Feb 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshhot of what's ahead for Big Pharma in the country
native1_300x100
lorem ipsum